|
|
| Introduction Following the patent expiries of angiotensin-II receptor blockers Datamonitor expects antihypertensives sales in the seven major markets to record sales of $29.5 billion in 2018, a drop of over $6 billion compared to 2008. Reasons to Purchase
|
Related Markets
Hypertension Reports
- Pulmonary Arterial Hypertension (PAH) Therapeutics - Global Drug Forecasts and Treatment Analysis to 2020
- Anti-Hypertensives Market to 2017 - Patent Expiries of Blockbusters such as Diovan, Micardis, Avapro and Atacand to Accelerate Erosion
- Portal Hypertension Therapeutics - Pipeline Assessment and Market Forecasts to 2019
- Hypertension Global Clinical Trials Review, H1, 2012
- Pulmonary Hypertension Global Clinical Trials Review, H1, 2012

